Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore Biomedical (NASDAQ: LFCR) announced on October 29, 2025 that it signed an agreement to execute a commercial site transfer and become the commercial supplier of choice for a leading injectable pharmaceutical product after regulatory requirements are satisfied. This is the second agreement with the same multinational customer in recent months. Lifecore also signed a separate pre-clinical formulation development agreement with an early-stage biotech, expanding its early-stage pipeline.
The deals are positioned to increase capacity utilization, broaden the commercial customer base, and leverage Lifecore’s fill-finish and regulatory track record as a U.S.-based CDMO for sterile injectables.
Lifecore Biomedical (NASDAQ: LFCR) ha annunciato il 29 ottobre 2025 di aver firmato un accordo per eseguire un trasferimento commerciale del sito e diventare il fornitore commerciale di scelta per un prodotto farmaceutico iniettabile leader, dopo che i requisiti normativi saranno soddisfatti. Questo è il secondo accordo con lo stesso cliente multinazionale negli ultimi mesi. Lifecore ha anche firmato un accordo separato di sviluppo di formulazioni precliniche con una biotech in fase iniziale, ampliando il suo pipeline in fase iniziale.
Gli accordi sono orientati ad aumentare l'utilizzo della capacità, a espandere la base di clienti commerciali e a sfruttare l'esperienza di Lifecore nel riempimento e rifinitura e nel percorso regolatorio come CDMO statunitense per iniettabili sterili.
Lifecore Biomedical (NASDAQ: LFCR) anunció el 29 de octubre de 2025 que firmó un acuerdo para ejecutar una transferencia de sitio comercial y convertirse en el proveedor comercial preferido para un producto farmacéutico inyectable líder tras cumplirse los requisitos regulatorios. Este es el segundo acuerdo con el mismo cliente multinacional en los últimos meses. Lifecore también firmó un acuerdo separado de desarrollo de formulaciones preclínicas con una biotecnológica en etapa temprana, expandiendo su cartera de proyectos en etapas iniciales.
Los acuerdos están posicionados para aumentar la utilización de la capacidad, ampliar la base de clientes comerciales y aprovechar el historial de Lifecore en llenado y acabado (fill-finish) y en el cumplimiento regulatorio como CDMO con sede en EE. UU. para inyectables estériles.
Lifecore Biomedical (NASDAQ: LFCR)은 2025년 10월 29일에 상업 현장 이전을 실행하고 규제 요건 충족 후 선도적 주사제 의약품의 상업적 선호 공급자가 되기로 합의했다고 발표했습니다. 이는 최근 몇 달 사이 동일한 다국적 고객과의 두 번째 합의입니다. Lifecore은 또한 초기 단계의 바이오테크 회사와의 별도 비임상 전 formulation 개발 협약을 체결하여 초기 파이프라인을 확장했습니다.
거래는 설비 가동률을 높이고, 상업적 고객 기반을 확대하며, 미국에 기반을 둔 무균 주사제 CDMO로서의 충진-마감 및 규제 실적을 활용하는 방향으로 자리매김하고 있습니다.
Lifecore Biomedical (NASDAQ: LFCR) a annoncé le 29 octobre 2025 avoir signé un accord visant à réaliser un transfert de site commercial et devenir le fournisseur commercial de référence pour un produit pharmaceutique injectable de premier plan après que les exigences réglementaires soient satisfaites. Il s'agit du deuxième accord avec le même client multinational au cours des derniers mois. Lifecore a également signé un accord distinct de développement de formulations précliniques avec une biotech en phase précoce, élargissant son pipeline en phase initiale.
Les accords visent à augmenter l'utilisation de la capacité, à élargir la base de clients commerciaux et à tirer parti de l'expérience de Lifecore en matière de remplissage et de finition ainsi que de son dossier réglementaire en tant que CDMO basé aux États-Unis pour les injectables stériles.
Lifecore Biomedical (NASDAQ: LFCR) kündigte am 29. Oktober 2025 an, dass es eine Vereinbarung unterzeichnet habe, um eine kommerzielle Standortübertragung durchzuführen und der kommerziell bevorzugte Lieferant für ein führendes injizierbares Pharmazeutikum zu werden, nachdem regulatorische Anforderungen erfüllt sind. Dies ist die zweite Vereinbarung mit demselben multinationalen Kunden in den letzten Monaten. Lifecore hat zudem eine separate Vor-Klinik-Formulierungsentwicklungsvereinbarung mit einem Biotech-Unternehmen in der Frühphase unterzeichnet und damit seine Early-Stage-Pipeline erweitert.
Die Deals sollen die Kapazitätsauslastung erhöhen, die kommerzielle Kundschaft erweitern und Lifecores Erfahrungen im Fill-Finish sowie den regulatorischen Track Record als US-amerikanischer CDMO für sterile Injektionsprodukte nutzen.
Lifecore Biomedical (NASDAQ: LFCR) أعلنت في 29 أكتوبر 2025 أنها وقعت اتفاقاً لتنفيذ نقل موقع تجاري وتصبح المورد التجاري المفضل لمنتج دوائي قابل للحقن رائد بعد استيفاء المتطلبات التنظيمية. وهذه هي الصفقة الثانية مع نفس العميل المتعدد الجنسيات في الأشهر الأخيرة. كما وقعت Lifecore اتفاق تطوير صياغة قبل الإكلينيكي منفصل مع شركة بيوتكنولوجي ناشئة، مما يوسع خط أنابيبها في المرحلة المبكرة.
تهدف الصفقات إلى زيادة استخدام القدرة، وتوسيع قاعدة العملاء التجارية، والاستفادة من سجل Lifecore في التعبئة والتغليف واتباع المتطلبات التنظيمية كمُشغّل تعاقدي للتصنيع (CDMO) في الولايات المتحدة للأدوية القابلة للحقن المعقمة.
Lifecore Biomedical (NASDAQ: LFCR) 于 2025年10月29日 宣布签署协议，执行商业现场转让并在满足监管要求后成为一款领先的注射剂药品的首选商业供应商。这是在最近几个月与同一跨国客户签署的第二份协议。Lifecore 还与一家早期生物技术公司签署了一个单独的前临床配方开发协议，扩大其早期管线。
这两笔交易的目的是提高 产能利用率、扩大商业客户基础，并利用 Lifecore 作为美国无菌注射剂CDMO的填充与成型及合规经验。
- Commercial site transfer signed for a leading injectable product
- Second agreement with the same multinational in recent months
- New pre-clinical formulation client added to early-stage pipeline
- Increases capacity utilization and expands into new modalities
- Commercial supply is contingent on completing the transfer and satisfying regulatory requirements
Insights
Lifecore won a commercial site transfer and a pre-clinical development deal, expanding its sterile injectable CDMO footprint and pipeline.
The agreement commits Lifecore to execute a full commercial site transfer for a leading injectable product and, once regulatory conditions are met, to become the product’s commercial supplier of choice. This sale represents the second contract from the same multinational in recent months and separately the company signed a pre-clinical formulation development agreement with an early-stage biotech, expanding both commercial and early‑stage pipelines.
Key dependencies include successful completion of the transfer and satisfaction of all regulatory requirements before commercial supply begins; those steps determine revenue recognition and timing. Watch for announcements confirming transfer milestones, regulatory approvals, and changes in capacity utilization because the deal explicitly links to broader capacity and modality expansion; there is no timeline disclosed in the release.
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product
Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months
Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer
CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed an agreement with a leading global pharmaceutical company. Under the terms of the agreement, Lifecore will transfer the commercial manufacturing for a leading injectable pharmaceutical product from the current manufacturer to Lifecore’s facilities. Upon completion of the transfer and satisfaction of all regulatory requirements, Lifecore will be the commercial supplier of choice for the product. This is the second agreement that Lifecore has signed with the same multinational organization in recent months, highlighting the company’s growing reputation for technical excellence, quality, and reliability in sterile injectables.
“This commercial site transfer is a significant accomplishment in our ongoing growth strategy as we work to expand our CDMO business and build long-term partnerships with leading global pharmaceutical companies. Importantly, this product will broaden our commercial customer base while also allowing us to increase our capacity utilization and expand into new modalities,” said Paul Josephs, chief executive officer of Lifecore. “We are thrilled to win this business, and believe that our proven regulatory track record and technical expertise in fill-finish operations were key determinants in our selection as the supplier of choice for this program.”
In additional business development news, Lifecore also announced the signing of a separate agreement with an early-stage biotechnology company to provide pre-clinical formulation development services. This new customer addition continues to grow the company’s early-stage program pipeline, addressing another one of Lifecore’s three growth strategies.
“As we look to capitalize on the strong tailwinds in our industry, we continue to see tremendous momentum generated by our business development team. Each new win serves to strengthen Lifecore’s position as a trusted, U.S.-based CDMO partner and reinforces our role in supporting domestic manufacturing for sterile injectables,” commented Mr. Josephs.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our growth strategy, expansion of our CDMO business, building of long-term partnerships with leading global pharmaceutical companies, broadening of our commercial customer base, increasing our capacity utilization, expanding into new modalities, growth of our early-stage program pipeline, momentum generated by our business development team, position as a trusted U.S.-based CDMO partner and our role in supporting domestic manufacturing capacity for sterile injectables are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, the timing and amount of future expenses, revenue, Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; our ability to maintain or expand our relationships with our current customers, including the impact of changes in consumer demand for the products we manufacture for our customers; our ability to grow and diversify our business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals, or for other reasons; our ability to comply with covenants under our credit agreements and to pay required interest and principal payments when due; our ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on our operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of our third-party suppliers; pharmaceutical industry market forces that may impact our customers’ success and continued demand for the products we produce for those customers; our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 25, 2025 (the “2025 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2025 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
What did Lifecore (LFCR) announce on October 29, 2025?
When will Lifecore (LFCR) become the commercial supplier for the injectable product?
How does the new agreement affect Lifecore's manufacturing capacity for LFCR?
Does the October 29, 2025 announcement involve repeat business for Lifecore (LFCR)?
What type of early-stage work did Lifecore (LFCR) win in this announcement?
What regulatory condition is noted in Lifecore's (LFCR) October 29, 2025 release?
